[{"id":"e90cec53-ae6c-493e-9af7-3f156a05c47e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02400281","created_at":"2021-01-18T11:27:08.882Z","updated_at":"2024-07-02T16:35:13.589Z","phase":"Phase 1/2","brief_title":"Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients","source_id_and_acronym":"NCT02400281","lead_sponsor":"Arog Pharmaceuticals, Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • azacitidine • etoposide IV • crenolanib (ARO-002) • idarubicin hydrochloride • mitoxantrone • fludarabine IV"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 09/01/2015","start_date":" 09/01/2015","primary_txt":" Primary completion: 07/15/2020","primary_completion_date":" 07/15/2020","study_txt":" Completion: 07/15/2020","study_completion_date":" 07/15/2020","last_update_posted":"2024-03-20"},{"id":"95b055b1-d7c0-4581-b32f-575eb60dd1f0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02283177","created_at":"2021-01-17T17:36:58.991Z","updated_at":"2024-07-02T16:35:21.166Z","phase":"Phase 2","brief_title":"A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations","source_id_and_acronym":"NCT02283177","lead_sponsor":"Arog Pharmaceuticals, Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • crenolanib (ARO-002) • daunorubicin • idarubicin hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 01/01/2015","start_date":" 01/01/2015","primary_txt":" Primary completion: 12/01/2019","primary_completion_date":" 12/01/2019","study_txt":" Completion: 12/01/2019","study_completion_date":" 12/01/2019","last_update_posted":"2024-02-02"},{"id":"3b2388de-8a3b-4895-8ff3-2c449923f3a7","acronym":"","url":"https://clinicaltrials.gov/study/NCT01522469","created_at":"2021-01-18T06:24:20.054Z","updated_at":"2024-07-02T16:35:21.896Z","phase":"Phase 2","brief_title":"Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations","source_id_and_acronym":"NCT01522469","lead_sponsor":"Arog Pharmaceuticals, Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e crenolanib (ARO-002)"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 07/01/2012","start_date":" 07/01/2012","primary_txt":" Primary completion: 08/01/2014","primary_completion_date":" 08/01/2014","study_txt":" Completion: 11/01/2014","study_completion_date":" 11/01/2014","last_update_posted":"2024-01-30"},{"id":"ffe95d39-a107-4d76-993c-37bb957aed8a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02400255","created_at":"2021-01-18T11:27:08.099Z","updated_at":"2024-07-02T16:35:25.967Z","phase":"Phase 2","brief_title":"Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients","source_id_and_acronym":"NCT02400255","lead_sponsor":"Arog Pharmaceuticals, Inc.","biomarkers":" HLA-DRB1","pipe":" | ","alterations":" FLT3 D835","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 D835"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e crenolanib (ARO-002)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 09/01/2015","start_date":" 09/01/2015","primary_txt":" Primary completion: 05/01/2022","primary_completion_date":" 05/01/2022","study_txt":" Completion: 05/01/2022","study_completion_date":" 05/01/2022","last_update_posted":"2023-12-18"},{"id":"c1091e4c-1522-4ef8-a73b-fc49b73dd693","acronym":"","url":"https://clinicaltrials.gov/study/NCT01657682","created_at":"2021-01-18T07:09:01.814Z","updated_at":"2024-07-02T16:35:27.592Z","phase":"Phase 2","brief_title":"A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations","source_id_and_acronym":"NCT01657682","lead_sponsor":"Arog Pharmaceuticals, Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e crenolanib (ARO-002) • hydroxyurea"],"overall_status":"Completed","enrollment":" Enrollment 56","initiation":"Initiation: 10/01/2012","start_date":" 10/01/2012","primary_txt":" Primary completion: 04/01/2019","primary_completion_date":" 04/01/2019","study_txt":" Completion: 04/01/2019","study_completion_date":" 04/01/2019","last_update_posted":"2023-11-30"},{"id":"87471c37-5ed6-46c4-9795-2812fbb13b4f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03250338","created_at":"2021-01-18T16:03:32.523Z","updated_at":"2024-07-02T16:36:30.932Z","phase":"Phase 3","brief_title":"Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML","source_id_and_acronym":"NCT03250338","lead_sponsor":"Arog Pharmaceuticals, Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3 D835","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3 D835"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • crenolanib (ARO-002) • idarubicin hydrochloride • mitoxantrone"],"overall_status":"Recruiting","enrollment":" Enrollment 322","initiation":"Initiation: 06/05/2018","start_date":" 06/05/2018","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2021-04-30"},{"id":"ec0044ab-0bc9-4c5a-8f2a-82680d79f10c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02847429","created_at":"2021-01-18T13:58:42.892Z","updated_at":"2024-07-02T16:36:35.764Z","phase":"Phase 3","brief_title":"Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST","source_id_and_acronym":"NCT02847429","lead_sponsor":"Arog Pharmaceuticals, Inc.","biomarkers":" PDGFRA","pipe":" | ","alterations":" PDGFRA D842V • PDGFRA mutation","tags":["PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDGFRA D842V • PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e crenolanib (ARO-002)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 08/01/2016","start_date":" 08/01/2016","primary_txt":" Primary completion: 08/01/2021","primary_completion_date":" 08/01/2021","study_txt":" Completion: 08/01/2021","study_completion_date":" 08/01/2021","last_update_posted":"2021-01-22"},{"id":"9da583ca-0cdc-4742-b307-c8c4e53e5ade","acronym":"","url":"https://clinicaltrials.gov/study/NCT02626364","created_at":"2021-01-18T12:45:51.033Z","updated_at":"2024-07-02T16:36:43.032Z","phase":"Phase 2","brief_title":"Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification","source_id_and_acronym":"NCT02626364","lead_sponsor":"Arog Pharmaceuticals, Inc.","biomarkers":" PDGFRA","pipe":"","alterations":" ","tags":["PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e crenolanib (ARO-002)"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 07/01/2020","primary_completion_date":" 07/01/2020","study_txt":" Completion: 07/01/2020","study_completion_date":" 07/01/2020","last_update_posted":"2020-07-20"},{"id":"27b4afa0-bb5c-444a-a0ae-37a94f6d8121","acronym":"","url":"https://clinicaltrials.gov/study/NCT03258931","created_at":"2021-01-18T16:06:01.096Z","updated_at":"2025-02-25T15:42:58.116Z","phase":"Phase 3","brief_title":"Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML","source_id_and_acronym":"NCT03258931","lead_sponsor":"Arog Pharmaceuticals, Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • midostaurin • crenolanib (ARO-002)"],"overall_status":"Recruiting","enrollment":" Enrollment 510","initiation":"Initiation: 08/15/2018","start_date":" 08/15/2018","primary_txt":" Primary completion: 11/01/2022","primary_completion_date":" 11/01/2022","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2020-05-22"},{"id":"f4922af1-9387-4965-9097-6bb80a183fca","acronym":"","url":"https://clinicaltrials.gov/study/NCT03324243","created_at":"2021-01-18T16:24:57.273Z","updated_at":"2024-07-02T16:37:04.008Z","phase":"Phase 2","brief_title":"A Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia","source_id_and_acronym":"NCT03324243","lead_sponsor":"Arog Pharmaceuticals, Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3 D835 • FLT3 I836","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3 D835 • FLT3 I836"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • crenolanib (ARO-002) • fludarabine IV"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/01/2018","start_date":" 01/01/2018","primary_txt":" Primary completion: 12/01/2020","primary_completion_date":" 12/01/2020","study_txt":" Completion: 12/01/2020","study_completion_date":" 12/01/2020","last_update_posted":"2019-01-10"},{"id":"4ed8fa9f-6144-4f0c-b60f-f530e4d76c83","acronym":"","url":"https://clinicaltrials.gov/study/NCT01243346","created_at":"2021-01-17T17:54:43.344Z","updated_at":"2024-07-02T16:37:09.392Z","phase":"Phase 2","brief_title":"Study of Crenolanib for the Treatment of Patients With Advanced GIST With the D842-related Mutations and Deletions in the PDGFRA Gene","source_id_and_acronym":"NCT01243346","lead_sponsor":"Arog Pharmaceuticals, Inc.","biomarkers":" PDGFRA","pipe":" | ","alterations":" PDGFRA D842V • PDGFRA mutation","tags":["PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDGFRA D842V • PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e crenolanib (ARO-002)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 04/01/2011","start_date":" 04/01/2011","primary_txt":" Primary completion: 07/01/2014","primary_completion_date":" 07/01/2014","study_txt":" Completion: 07/01/2014","study_completion_date":" 07/01/2014","last_update_posted":"2018-06-28"},{"id":"a0c28c79-4f79-4963-80d6-aeb7971347fe","acronym":"","url":"https://clinicaltrials.gov/study/NCT02270788","created_at":"2021-01-18T10:40:49.035Z","updated_at":"2024-07-02T16:37:17.373Z","phase":"Phase 1","brief_title":"Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies","source_id_and_acronym":"NCT02270788","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" FLT3 • MPO","pipe":"","alterations":" ","tags":["FLT3 • MPO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • cytarabine • crenolanib (ARO-002) • leucovorin calcium"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 04/02/2015","start_date":" 04/02/2015","primary_txt":" Primary completion: 10/17/2016","primary_completion_date":" 10/17/2016","study_txt":" Completion: 10/17/2016","study_completion_date":" 10/17/2016","last_update_posted":"2017-10-03"}]